Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 9/20 | 0.52 |
| ▸ | TDP2 | O95551 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.35 |
| ▸ | GALR1 | P47211 | 1/20 | 0.35 |
| ▸ | CHKA | P35790 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4596154 | 0.86 | KIF11 (0.41) | KIF11TDP2CA9CA12CHRNB2 | |
| SCHEMBL4898485 | 0.77 | KIF11 (0.59) | KIF11TDP2CA9CA12CHRNB2 | |
| SCHEMBL6911317 | 0.74 | CYP11B2 (0.42) | — | |
| SCHEMBL4596437 | 0.72 | KIF11 (0.65) | KIF11TDP2CHRNB2CHRNA4 | |
| SCHEMBL6910702 | 0.72 | CYP11B1 (0.60) | TDP2 | |
| SCHEMBL4898372 | 0.71 | KIF11 (0.72) | KIF11TDP2CHRNB2CHRNA4ASIC3 | |
| SCHEMBL1903306 | 0.70 | KIF11 (0.80) | KIF11TDP2 | |
| SCHEMBL4596526 | 0.70 | KIF11 (0.57) | KIF11TDP2CHRNB2CHRNA4ASIC3 | |
| SCHEMBL1396616 | 0.69 | KIF11 (1.00) | KIF11TDP2 | |
| SCHEMBL4596871 | 0.69 | KIF11 (0.59) | KIF11TDP2CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | claimed |
| EP-1874753-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-09 | — | — | EP | claimed |
| WO-2006113432-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | claimed |
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | disclosed |
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | disclosed |
| EP-1874753-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006113432-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176830-A1 | Compounds, Compositions, and Methods | ALPP, PCNA, MKI67 | KIF11 562/4885TDP2 1033/4885CA9 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.